CureVac AG   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Tubingen Germany (2000)

Organization Overview

First Clinical Trial
2009
NCT00831467
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

CureVac | CureVac AG

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Adenoid Cystic (Phase 1)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 1)

Coronavirus Infections (Phase 3)

Lung Neoplasms (Phase 2)

Melanoma (Phase 1)

Prostatic Neoplasms (Phase 2)

Rabies (Phase 1)

Severe Acute Respiratory Syndrome (Phase 3)

Skin Neoplasms (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 25
  • # of Trial APIs: 21